Healthy Q2 and H1; resulting in consecutive guidance upgrade
04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."
Pages
67
Language
English
Published on
04/08/22
You may also be interested by these reports :
28/10/26
The change in our NAV calculation reflects a change of analyst covering the stock. Our NAV/SOTP valuation is now based on a new breakdown separating ...
27/10/26
Despite some near-term caution (discussed in the EPS section), we continue to see sizeable upside for bioMerieux, supported by its dominance in ...
23/10/26
SSB delivered an in-line Q3 26, with revenue and underlying EBITDA in line with consensus. Consumables continued to lead growth, while equipment grew ...
22/10/26
After a failed bid by Thermo Fisher and persistent rumours in recent years, Qiagen shareholders now have a second opportunity. Although shareholder ...